These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26058730)

  • 1. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
    Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
    Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
    [No Abstract]   [Full Text] [Related]  

  • 2. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
    Lentz SR; Cerqueira M; Janic D; Kempton C; Matytsina I; Misgav M; Oldenburg J; Ozelo M; Recht M; Rosholm A; Savic A; Suzuki T; Tiede A; Santagostino E
    Haemophilia; 2016 Sep; 22(5):e445-9. PubMed ID: 27291066
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).
    Ozelo M; Chowdary P; Regnault A; Busk AK
    Haemophilia; 2015 Jul; 21(4):451-7. PubMed ID: 25677761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates from guardian™: a comprehensive registration programme.
    Ozelo MC
    Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
    Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
    Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
    Boban A; Hermans C
    Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
    [No Abstract]   [Full Text] [Related]  

  • 13. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
    Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
    Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
    Tiede A; Klamroth R; Oldenburg J
    Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L; Pollmann H; Becker T
    Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study.
    Petrini P; Rylander C
    Haemophilia; 2009 Jan; 15(1):175-83. PubMed ID: 18752534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.